Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.38 |
| ▸ | BRAF | P15056 | 8/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23368147 | 0.83 | CYP17A1 (0.46) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL30203106 | 0.83 | CYP17A1 (0.46) | KDRBRAFMAPK14TNNI3KFLT1 | |
| SCHEMBL23368156 | 0.81 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL23355367 | 0.78 | KDM4E (0.34) | NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL4684136 | 0.74 | PARP10 (0.44) | BRAFMAPK14NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2095013 | 0.73 | RAB9A (0.58) | NPC1RAB9ASMN1; SMN2GAAPOLB | |
| SCHEMBL21612977 | 0.73 | SCN4A (0.34) | — | |
| SCHEMBL24037921 | 0.72 | ALDH1A1 (0.38) | — | |
| SCHEMBL519186 | 0.72 | MAPT (0.48) | NPC1RAB9ASMN1; SMN2GAAPOLB | |
| SCHEMBL15543233 | 0.72 | MAPK14 (0.50) | KDRBRAFMAPK14FLT1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3822263-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | KDR 20/4885BRAF 28/4885MAPK14 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.